Drug development for neuromuscular disorders: the essential role of preclinical research

Researchers discussed preclinical models and drug development for neuromuscular disorders (NMDs) in a panel discussion held at WMS2020.

Highlights of the discussion were as follows:

    Dr Dominic Wells (Royal Veterinary College, London, UK) discussed preclinical study designs. “Some previous studies have had flaws in experimental design,” he said. “We need to ensure we design good experiments to get good information. As humans, we have cognitive biases to see results that really aren’t there, and I think we have to be very careful to avoid those biases.”